Cell Phone-Enabled Diagnostics: mHealth Applications in IVD

Mobile health has reached in vitro diagnostics and as this Kalorama report details, may change the industry forever. Over the years, the introduction of transportable, portable, and handheld instruments has resulted in the migration of clinical lab testing from the central lab to a range of environments including self-testing, community clinics, the workplace, home, disaster care and most recently, retail convenience clinics. In spite of promotional materials that emphasize ease of use, the majority of currently available POC tests require a fair amount of medical lab know-how, especially in the interpretation of the test result.

The goal is for cell phone-enabled test devices to provide primary care for underserved areas in developed countries and low income developing markets. Especially since new technologies are allowing POC devices to produce quantitative lab-quality test results that can be transferred automatically to an information system, to a remote caregiver service for consultation or to an electronic medical record.

Get your copy of this report @ http://www.reportsnreports.com/reports/190904-cell-phone-enabled-diagnostics-mhealth-applications-in-ivd.html

Report Details:
Published: August 2012
No. of Pages: 130
Price: Single User License – US$2500 Corporate User License – US$5000

This report, Cell Phone-Enabled Diagnostics: mHealth Applications in IVD tracks cell phone-enabled products on the market and how they will affect the existing diagnostic industry. As part of this report's coverage, the following is included:

Representative Cell Phone-Enabled Products in Diabetes, Immunoassays, Hematology, Histology and Molecular IVD.
· Market Outlook for mHealth In IVD and The Best Areas For Commercial Success
· Description of the Market Leaders, Organizations and Companies In This Market.
· Government and Payer Support for mHealth
· The Role of New technologies in the Evolution of POCT
· Consumer, Physician and Payor Willingness
· How Upstarts are Faring Vs. Established Products
· Analyst Conclusions

Kalorama lead diagnostic analyst Shara Rosen, R.T., MBA presents the new developments in the convergence of IVD and mobile technologies in this unique overview of the mHealth IVD market. The company profile chapter provides a selection of companies and organizations that are pioneering the use of specially designed digital and or wireless and cell phone-enabled test devices for clinical diagnostic applications. The most advanced applications are available for glucose self-testing and the transmission of stained slide images in histology, microbiology and hematology for remote consultation with and analysis by an expert. The following companies are profiled.

· Accuster Technologies Pvt. Ltd.
· AgaMatrix, Inc.
· Alere
· ARKRAY
· ARUP Laboratories
· Axxin
· BBInternational
· BIO-key International, Inc.
· BodyTel Europe GmbH
· California Institute of Technology (Caltech)
· CellScope
· CellScope Inc.
· Clearbridge BioLoc Pte Ltd
· Columbia University
· DNAFORM
· eSTI – (Electronic self-testing instruments)
· Entra Health Systems
· Freescale Semiconductor
· Bill and Melinda Gates Foundation
· Gene-Z
· Genomic Health, Inc.
· GenPrime, Inc.
· Gentag Inc.
· GlySens Incorporated
· Harvard University Medical School
· Heidelberger-Medical-Marketing GmbH (HMM GmbH)
· HolGenTech Inc.
· Holomic LLC (formerly Microskia)
· Infopia Co Ltd
· Intelligent Optical Systems, Inc.
· Korea Advanced Institute of Science of Technology (KAIST)
· Labonfoil Consortium
· Leica Microsystems
· Lifescan Inc.
· Massachusetts General Hospital
· MAVAND Solutions GmbH
· MEDIWISS Analytic GmbH
· Medtronic Inc.
· MycroLab Pty Ltd.
· NextLab
· Oasis Diagnostics
· Oasis Scientific, Inc.
· QIAGEN N.V.
· QuantuMDx Group Limited
· Sano Intelligence
· Skannex
· TelCare Inc.
· Università Commerciale Luigi Bocconi
· University of Arizona
· University of Washington
· X out TB

The companies selected are those that are pioneers in their field and that provide an overview of the innovations underway in cell phone-enabled diagnostics. The information presented in this report is derived on publicly available information sources such as company, government, and medical organization reports. The analysis is based on the author's industry knowledge combined with literature searches and interviews with industry professionals and experts in the areas of POC tests, mobile health, decentralized healthcare and healthcare economics.

The use of cell phone-enabled diagnostics is in the earlystages of development in both developed and developing world markets. Thereforethis market analysis is somewhat speculative.In spite of the buzz about the use of cell phone-enabled test devices inmHealth, there are so many combinations of devices, applications and marketsthat the market is hard to define with precision.

Current mHealth programs that use cell phones as part of thediagnostic process (with the exception of glucose self-testing) have beeninitiated as pilot projects in developing countries with little or no concreteplans for their continuation as fully funded and government supportedhealthcare services.

Further, since much of the current mHealth products aredelivered as smartphone apps and services that are offered as part of a productoffering, it is difficult to estimate the size of the opportunity. Nevertheless, this report takes a bold lookinto the possibilities for cell phone-enabled testing in the next five to tenyears.




Explore more reports on Healthcare @ http://www.reportsnreports.com/market-research/healthcare/

Market and Product Forecasts: Asthma in China – Market set to fragment as novel therapies launch

The increasing prevalence of asthma and launch of new therapies will boost the Chinese asthma market (Tier 1 and Tier 2 cities) from $331m in 2012 to $489m by 2021. A number of novel products will increase the product offering on the market, however, with only a fraction of the patient pool market receiving asthma treatment, considerable untapped patient potential will remain.

Features and benefits

• Access Datamonitor’s patient-based asthma market forecast for Chinese Tier 1 and Tier cities, with transparent methodology and clear assumptions.
• Explore the current and future market size of asthma in China and see how pipeline products will impact the market.
• Gain insight into asthma market dynamics in China, and see where untapped market potential remains.
• Understand which factors are driving growth in the Chinese asthma market, and what challenges marketed and pipeline products face.

Highlights

Datamonitor forecasts the Chinese Tier 1 and Tier 2 asthma market to grow from $331m in 2012 to $489m by 2021. Despite this growth, the asthma market will reach only a fraction of its potential. Still, with a growing patient pool, unique market dynamics, and increasing treatment coverage, the asthma market in China is becoming more attractive.
Datamonitor expects that four new therapies will enter the Chinese market over 2012–21, including the first once-daily ICS/LABA combinations and biologic anti-asthmatics. While biologics are clinically attractive, their commercial potential will be held back by their relatively high price and limited patient pool.
Datamonitor estimates that in 2012 Seretide and Singulair topped the market with sales of $59m and $65m, respectively, together capturing 37% of the Chinese market (Tier 1 and Tier 2 cities). Datamonitor forecasts that Seretide will face competition from once-daily ICS/LABAs after 2015, but Singulair will maintain its market dominance.

Your key questions answered

• How large is the current asthma market size in Chinese Tier 1 and Tier 2 cities and how is it expected to change over the next 10 years?
• What restrictions will novel therapies face upon launching in the Chinese asthma market?
• How will current market leaders be impacted by additional product launches?
• What role do Chinese regulations play in asthma market dynamics, and how does this impact product use?

Buy your copy of this report @ http://www.reportsnreports.com/reports/184111-market-and-product-forecasts-asthma-in-china-market-set-to-fragment-as-novel-therapies-launch.html

Report Details:
Published: July 2012
Price: Single User License: US$ 11400       Corporate User License: US$ 28500

Healthcare Cloud Computing Market (Clinical, EMR, SaaS, Private, Public, Hybrid) - Global Trends, Challenges, Opportunities & Forecasts (2012 – 2017)

Technologies in the healthcare IT industry are converging with time and are far outpacing the legacy systems used by hospitals and healthcare providers. Pronouncements by various countries such as American Recovery and Reinvestment Act of 2009 (ARRA) laid down by the U.S. government are encouraging businesses in the healthcare industry to utilize certain applications of electronic records. Recently, cloud technology has started replacing these legacy systems and offers easier and faster access to this data as defined by the way it is stored i.e. public, private or hybrid.

Cloud computing offers significant benefits to the healthcare sector; Doctor’s clinics, hospitals, and health clinics require quick access to computing and large storage facilities which are not provided in the traditional settings, moreover healthcare data needs to be shared across various settings and geographies which further burdens the healthcare provider and the patient causing significant delay in treatment and loss of time. Cloud caters to all these requirements thus providing the healthcare organizations an incredible opportunity to improve services to their customers, the patients, to share information more easily than ever before, and improve operational efficiency at the same time. The flip side of this advantage is that healthcare data has specific requirements such as security, confidentiality, availability to authorized users, traceability of access, reversibility of data, and long-term preservation. Hence, cloud vendors need to account for all these while conforming to regulations such as HIPAA and Meaningful use.

All the above factors bring the market for cloud computing to grow at a CAGR of 20.5% from 2010 to 2017 in healthcare. Although cloud computing offers significant advantages to HCOs and other stakeholders, it has set of restraints. Security of patient information, interoperability and compliance with government regulations are some of the factors which are slowing down this market.

Cloud technology has been adopted only in certain regions of the world, the majority share being held by the developed nations. The geographies studied include North America, Europe, Asia, and ROW. North America accounts for the lion’s share in the cloud computing market with U.S. being the largest contributor to this region.

The healthcare cloud computing market is a fragmented one with no player occupying a share more than 5%. A few players in this market are CareCloud (U.S.), Carestream Health, Inc. (U.S.), Merge Healthcare, Inc. (U.S.), GE Healthcare (U.K.), and Agfa Healthcare (Belgium).

The scope of the report spans the cloud computing market in healthcare which comprises:

    Global healthcare cloud computing market, by applications
        Clinical Information Systems (CIS)
            Electronic Medical Records (EMR)
            Picture Archiving and Communication System (PACS)
            Radiology Information System (RIS)
            Computerized Physician Order Entry (CPOE)
            Laboratory Information System (LIS)
            Pharmacy Information System (PIS)
            Others
        Non Clinical Information Systems (NCIS)
            Revenue Cycle Management (RCM)
            Automatic Patient Billing (APB)
            Cost accounting
            Payroll
            Claims management

    Global healthcare cloud computing market, by pricing model
        Pay-as-you-go
        Spot pricing
    Global healthcare cloud computing market, by deployment model
        Public cloud
        Private cloud
        Hybrid cloud
     Global healthcare cloud computing market, by components
        Software
        Hardware
        Services
     Global healthcare cloud computing market, by service model
        Software-as-a-Service (SaaS)
        Platform-as-a-Service (PaaS)
        Infrastructure-as-a-Service (IaaS)
     Healthcare cloud computing market, by geography
        North America
        Europe
        Asia
        Rest of the World (ROW)

Each section of the report offers market data for the various market segments and geographies. It also provides market trends with respect to drivers, restraints, and opportunities.

• Buy your copy of this report @ http://www.reportsnreports.com/reports/173481-healthcare-cloud-computing-clinical-emr-saas-private-public-hybrid-market-global-trends-challenges-opportunities-forecasts-2012-2017.html.
• Request A Sample of the report for analysis before making your purchase decision @ http://www.reportsnreports.com/contacts/RequestSample.aspx?name=173481

Table of Contents for the report on Cloud Computing Market in Healthcare Industry include:

1 INTRODUCTION
  1.1 KEY TAKE-AWAYS
  1.2 REPORT DESCRIPTION
  1.3 MARKETS COVERED
  1.4 STAKEHOLDERS
  1.5 RESEARCH METHODOLOGY
      1.5.1 MARKET SIZE
      1.5.2 KEY DATA POINTS FROM SECONDARY SOURCES
      1.5.3 KEY DATA POINTS FROM PRIMARY SOURCES
      1.5.4 ASSUMPTIONS

2 EXECUTIVE SUMMARY

3 MARKET OVERVIEW
  3.1 INTRODUCTION
  3.2 EVOLUTION OF CLOUD COMPUTING IN HEALTHCARE
  3.3 MARKET SEGMENTATION
  3.4 MARKET DYNAMICS
      3.4.1 DRIVERS
            3.4.1.1 Reforms of various countries directly benefit healthcare IT and affect the healthcare budgets
            3.4.1.2 Pay-as-you-go model and cost-efficiency of cloud
            3.4.1.3 Improvements in storage technology
            3.4.1.4 Greater flexibility and scalability of data
      3.4.2 RESTRAINTS
            3.4.2.1 Safeguarding patient information is an imperative task
            3.4.2.2 Interoperability & standardization
            3.4.2.3 Migration from legacy systems is considered a tedious task by providers
      3.4.3 OPPORTUNITIES & TRENDS
            3.4.3.1 Telecloud
            3.4.3.2 Formation of accountable care organizations
  3.5 MARKET SHARE ANALYSIS

4 CLOUD COMPUTING BENEFITS & CHALLENGES
  4.1 BENEFITS/ADVANTAGES
      4.1.1 ON-DEMAND NETWORK ACCESS & DYNAMICALLY CONFIGURABLE COMPUTING RESOURCES
      4.1.2 AVOIDS USE OF RACKSPACE IN HCO DATACENTER
      4.1.3 PAY-AS-USE PRICING FOR HCOS
      4.1.4 AIDS IN DISASTER RECOVERY
  4.2 CHALLENGES
      4.2.1 LACK OF GUARANTEED AVAILABILITY OR RELIABILITY OF CLOUD SERVICE
      4.2.2 MAJOR OUTAGES CAN AFFECT THE FUNCTIONING OF HCO’S
      4.2.3 TCO MODEL FOR HCOS CANNOT BE FIXED LIKE OTHER INDUSTRY VERTICALS
      4.2.4 HCOS NEED TO BE DEPENDENT ON VENDOR SECURITY

5 GLOBAL CLOUD COMPUTING HEALTHCARE MARKET, BY APPLICATIONS
  5.1 INTRODUCTION
  5.2 CLINICAL INFORMATION SYSTEMS (CIS)
      5.2.1 ELECTRONIC MEDICAL RECORD (EMR)
      5.2.2 PICTURE ARCHIVING & COMMUNICATION SYSTEM (PACS)
      5.2.3 RADIOLOGY INFORMATION SYSTEM (RIS)
      5.2.4 COMPUTERIZED PHYSICIAN ORDER ENTRY (CPOE)
      5.2.5 LABORATORY INFORMATION SYSTEM (LIS)
      5.2.6 PHARMACY INFORMATION SYSTEM (PIS)
      5.2.7 OTHERS
  5.3 NON CLINICAL INFORMATION SYSTEMS (NCIS)
      5.3.1 REVENUE CYCLE MANAGEMENT (RCM)
      5.3.2 AUTOMATIC PATIENT BILLING (APB)
      5.3.3 PAYROLL
      5.3.4 CLAIMS MANAGEMENT
      5.3.5 COST ACCOUNTING

6 GLOBAL CLOUD COMPUTING HEALTHCARE MARKET, BY DEPLOYMENT MODELS
  6.1 INTRODUCTION
  6.2 PRIVATE CLOUD
      6.2.1 DRIVERS & CHALLENGES
            6.2.1.1 Driver
                    6.2.1.1.1 Interoperability & sharing of data
            6.2.1.2 Challenge
                    6.2.1.2.1 Data security poses a huge dilemma for healthcare providers
      6.2.2 EMERGING TREND
  6.3 PUBLIC CLOUD
      6.3.1 CHALLENGE
            6.3.1.1 Security and privacy concerns
      6.3.2 MARKET TRENDS
  6.4 HYBRID CLOUD
  6.5 COMMUNITY CLOUD

7 GLOBAL CLOUD COMPUTING HEALTHCARE MARKET, BY SERVICE MODELS
  7.1 INTRODUCTION
  7.2 SOFTWARE-AS-A-SERVICE (SaaS)
  7.3 INFRASTRUCTURE-AS-A-SERVICE (IaaS)
  7.4 PLATFORM-AS-A-SERVICE (PaaS)

8 CLOUD COMPUTING HEALTHCARE MARKET, BY PRICING MODELS
  8.1 INTRODUCTION
  8.2 PRICING MODELS
      8.2.1 PAY-AS-YOU-GO MODEL
      8.2.2 SPOT PRICING MODEL
  8.3 COST COMPONENTS ANALYSIS FOR HEALTHCARE MARKET
      8.3.1 SOFTWARE
      8.3.2 HARDWARE
      8.3.3 NETWORK
      8.3.4 BACK-UP POWER
      8.3.5 INSTALLATION SERVICES & ONGOING IT SUPPORT

9 GLOBAL CLOUD COMPUTING HEALTHCARE MARKET, BY COMPONENTS
  9.1 INTRODUCTION
  9.2 SOFTWARE
      9.2.1 CLINICAL INFORMATION SYSTEMS (CIS)
      9.2.2 NON CLINICAL INFORMATION SYSTEMS OR NON CLINICAL HEALTHCARE SYSTEMS (NCIS OR NCHS)
      9.2.3 OTHERS
  9.3 HARDWARE
      9.3.1 ACCESS DEVICES
      9.3.2 PERIPHERALS
      9.3.3 SERVERS
      9.3.4 STORAGE DEVICES
      9.3.5 NETWORKING DEVICES
  9.4 SERVICES
      9.4.1 CONSULTING
      9.4.2 IMPLEMENTATION SERVICES
      9.4.3 POST-SALE & MAINTENANCE
      9.4.4 TRAINING SERVICES

10 GEOGRAPHIC ANALYSIS
  10.1 INTRODUCTION
  10.2 NORTH AMERICA
  10.3 EUROPE
  10.4 ASIA
  10.5 ROW

11 COMPETITIVE LANDSCAPE
  11.1 INTRODUCTION
  11.2 MERGERS & ACQUISITIONS
  11.3 COLLABORATIONS/PARTNERSHIPS/AGREEMENTS/JOINT VENTURES
  11.4 NEW PRODUCTS DEVELOPMENT
  11.5 OTHERS

12 COMPANY PROFILES
  12.1 AGFA HEALTHCARE
      12.1.1 OVERVIEW
      12.1.2 FINANCIALS
      12.1.3 PRODUCTS & SERVICES
      12.1.4 STRATEGY
      12.1.5 DEVELOPMENTS
  12.2 APPLE, INC.
      12.2.1 OVERVIEW
      12.2.2 FINANCIALS
      12.2.3 PRODUCTS & SERVICES
      12.2.4 STRATEGY
      12.2.5 DEVELOPMENTS
  12.3 ATHENAHEALTH, INC.
      12.3.1 OVERVIEW
      12.3.2 FINANCIALS
      12.3.3 PRODUCTS & SERVICES
      12.3.4 STRATEGY
      12.3.5 DEVELOPMENTS
  12.4 CARECLOUD CORPORATION
      12.4.1 OVERVIEW
      12.4.2 FINANCIALS
      12.4.3 PRODUCTS & SERVICES
      12.4.4 STRATEGY
      12.4.5 DEVELOPMENTS
  12.5 CARESTREAM HEALTH, INC.
      12.5.1 OVERVIEW
      12.5.2 FINANCIALS
      12.5.3 PRODUCTS & SERVICES
      12.5.4 STRATEGY
      12.5.5 DEVELOPMENTS
  12.6 CISCO SYSTEMS, INC.
      12.6.1 OVERVIEW
      12.6.2 FINANCIALS
      12.6.3 PRODUCTS & SERVICES
      12.6.4 STRATEGY
      12.6.5 DEVELOPMENTS
  12.7 CLEARDATA NETWORKS
      12.7.1 OVERVIEW
      12.7.2 FINANCIALS
      12.7.3 PRODUCTS & SERVICES
      12.7.4 STRATEGY
      12.7.5 DEVELOPMENTS
  12.8 COVISINT
      12.8.1 OVERVIEW
      12.8.2 FINANCIALS
      12.8.3 PRODUCTS & SERVICES
      12.8.4 STRATEGY
      12.8.5 DEVELOPMENTS
  12.9 DELL, INC.
      12.9.1 OVERVIEW
      12.9.2 FINANCIALS
      12.9.3 PRODUCTS & SERVICES
      12.9.4 STRATEGY
      12.9.5 DEVELOPMENTS
  12.10 EMC CORPORATION
      12.10.1 OVERVIEW
      12.10.2 FINANCIALS
      12.10.3 PRODUCTS & SERVICES
      12.10.4 STRATEGY
      12.10.5 DEVELOPMENTS
  12.11 GLOBAL NET ACCESS (GNAX) HEALTH
      12.11.1 OVERVIEW
      12.11.2 FINANCIALS
      12.11.3 PRODUCTS & SERVICES
      12.11.4 STRATEGY
      12.11.5 DEVELOPMENTS
  12.12 HEWLETT-PACKARD COMPANY
      12.12.1 OVERVIEW
      12.12.2 FINANCIALS
      12.12.3 PRODUCTS & SERVICES
      12.12.4 STRATEGY
      12.12.5 DEVELOPMENTS
  12.13 IBM CORPORATION
      12.13.1 OVERVIEW
      12.13.2 FINANCIALS
      12.13.3 PRODUCT & SERVICES
      12.13.4 STRATEGY
      12.13.5 DEVELOPMENTS
  12.14 INTEL CORPORATION
      12.14.1 OVERVIEW
      12.14.2 FINANCIALS
      12.14.3 PRODUCTS & SERVICES
      12.14.4 STRATEGY
  12.15 IRON MOUNTAIN, INC.
      12.15.1 OVERVIEW
      12.15.2 FINANCIALS
      12.15.3 PRODUCTS & SERVICES
      12.15.4 STRATEGY
      12.15.5 DEVELOPMENTS
  12.16 MERGE HEALTHCARE, INC.
      12.16.1 OVERVIEW
      12.16.2 FINANCIALS
      12.16.3 PRODUCTS & SERVICES
      12.16.4 STRATEGY
      12.16.5 DEVELOPMENTS
  12.17 MICROSOFT CORPORATION
      12.17.1 OVERVIEW
      12.17.2 FINANCIALS
      12.17.3 PRODUCTS & SERVICES
      12.17.4 STRATEGY
      12.17.5 DEVELOPMENTS
  12.18 ORACLE CORPORATION
      12.18.1 OVERVIEW
      12.18.2 FINANCIALS
      12.18.3 PRODUCTS & SERVICES
      12.18.4 STRATEGY
      12.18.5 DEVELOPMENTS
  12.19 RACKSPACE HOSTING, INC.
      12.19.1 OVERVIEW
      12.19.2 FINANCIALS
      12.19.3 PRODUCTS & SERVICES
      12.19.4 STRATEGY
  12.20 VMWARE, INC.
      12.20.1 OVERVIEW
      12.20.2 FINANCIALS
      12.20.3 PRODUCTS & SERVICES
      12.20.4 STRATEGY
      12.20.5 DEVELOPMENTS

LIST OF TABLES

TABLE 1 CLOUD COMPUTING HEALTHCARE MARKET REVENUE, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 2 CLOUD COMPUTING HEALTHCARE MARKET REVENUE, BY APPLICATIONS, 2010 – 2017 ($MILLION)
TABLE 3 CIS CLOUD COMPUTING MARKET REVENUE, BY TYPES, 2010 – 2017 ($MILLION)
TABLE 4 CIS CLOUD COMPUTING MARKET REVENUE, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 5 EMR SOFTWARE CLOUD COMPUTING MARKET REVENUE, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 6 PACS SOFTWARE CLOUD COMPUTING MARKET REVENUE, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 7 RIS SOFTWARE CLOUD COMPUTING MARKET REVENUE, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 8 CPOE SOFTWARE CLOUD COMPUTING MARKET REVENUE, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 9 LIS SOFTWARE CLOUD COMPUTING MARKET REVENUE, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 10 PIS SOFTWARE CLOUD COMPUTING MARKET REVENUE, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 11 NCIS CLOUD COMPUTING MARKET REVENUE, BY TYPES, 2010 – 2017 ($MILLION)
TABLE 12 NCIS CLOUD COMPUTING MARKET REVENUE, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 13 RCM CLOUD COMPUTING MARKET REVENUE, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 14 APB SOFTWARE CLOUD COMPUTING MARKET REVENUE, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 15 PAYROLL SOFTWARE CLOUD COMPUTING MARKET REVENUE, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 16 CLAIMS MANAGEMENT SOFTWARE CLOUD COMPUTING MARKET REVENUE, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 17 COST ACCOUNTING CLOUD COMPUTING MARKET REVENUE, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 18 GLOBAL CLOUD COMPUTING HEALTHCARE MARKET REVENUE, BY DEPLOYMENT MODELS, 2010 – 2017 ($MILLION)
TABLE 19 PRIVATE CLOUD HEALTHCARE MARKET REVENUE, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 20 PRIVATE CLOUD HEALTHCARE MARKET REVENUE, BY CIS APPLICATIONS, 2010 – 2017 ($MILLION)
TABLE 21 PRIVATE CLOUD HEALTHCARE MARKET REVENUE, BY NCIS APPLICATIONS, 2010 – 2017 ($MILLION)
TABLE 22 PUBLIC CLOUD HEALTHCARE MARKET REVENUE, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 23 PUBLIC CLOUD HEALTHCARE MARKET REVENUE, BY CIS APPLICATIONS, 2010 – 2017 ($MILLION)
TABLE 24 PUBLIC CLOUD HEALTHCARE MARKET REVENUE, BY NCIS APPLICATIONS, 2010 – 2017 ($MILLION)
TABLE 25 HYBRID CLOUD HEALTHCARE MARKET REVENUE, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 26 HYBRID CLOUD HEALTHCARE MARKET REVENUE, BY CIS APPLICATIONS, 2010 – 2017 ($MILLION)
TABLE 27 HYBRID CLOUD HEALTHCARE MARKET REVENUE, BY NCIS APPLICATIONS, 2010 – 2017 ($MILLION)
TABLE 28 GLOBAL CLOUD COMPUTING MARKET REVENUE, BY SERVICE MODELS, 2010 – 2017 ($MILLION)
TABLE 29 GLOBAL SaaS HEALTHCARE MARKET REVENUE, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 30 GLOBAL IaaS HEALTHCARE MARKET REVENUE, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 31 GLOBAL PaaS HEALTHCARE MARKET REVENUE, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 32 GLOBAL CLOUD COMPUTING HEALTHCARE MARKET REVENUE, BY PRICING MODELS, 2010 – 2017 ($MILLION)
TABLE 33 PAY-AS-YOU-GO MODEL HEALTHCARE MARKET REVENUE, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 34 SPOT PRICING MODEL HEALTHCARE MARKET REVENUE, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 35 CLOUD COMPUTING HEALTHCARE MARKET, BY COMPONENTS, 2010 – 2017 ($MILLION)
TABLE 36 CLOUD SOFTWARE HEALTHCARE MARKET REVENUE, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 37 CLOUD COMPUTING SOFTWARE HEALTHCARE MARKET, BY DEPLOYMENT MODELS, 2010 – 2017 ($MILLION)
TABLE 38 CLOUD HARDWARE MARKET HEALTHCARE REVENUE, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 39 CLOUD COMPUTING HARDWARE HEALTHCARE MARKET, BY DEPLOYMENT MODELS, 2010 – 2017 ($MILLION)
TABLE 40 CLOUD SERVICES HEALTHCARE MARKET REVENUE, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 41 CLOUD COMPUTING HEALTHCARE SERVICES MARKET, BY DEPLOYMENT MODELS, 2010 – 2017 ($MILLION)
TABLE 42 CLOUD COMPUTING HEALTHCARE MARKET REVENUE, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 43 NORTH AMERICA: CLOUD COMPUTING HEALTHCARE MARKET REVENUE, BY APPLICATIONS, 2010 – 2017 ($MILLION)
TABLE 44 NORTH AMERICA: CLOUD COMPUTING HEALTHCARE MARKET REVENUE, BY DEPLOYMENT MODELS, 2010 – 2017 ($MILLION)
TABLE 45 NORTH AMERICA: CLOUD COMPUTING HEALTHCARE MARKET REVENUE, BY COMPONENTS, 2010 – 2017 ($MILLION)
TABLE 46 NORTH AMERICA: CLOUD COMPUTING HEALTHCARE MARKET REVENUE, BY SERVICE MODELS, 2010 – 2017 ($MILLION)
TABLE 47 NORTH AMERICA: CIS CLOUD COMPUTING MARKET REVENUE,  BY TYPES, 2010 – 2017 ($MILLION)
TABLE 48 NORTH AMERICA: NCIS CLOUD COMPUTING MARKET REVENUE, BY TYPES, 2010 – 2017 ($MILLION)
TABLE 49 NORTH AMERICA: CLOUD COMPUTING HEALTHCARE MARKET REVENUE, BY PRICING MODELS, 2010 – 2017 ($MILLION)
TABLE 50 EUROPE: CLOUD COMPUTING HEALTHCARE MARKET REVENUE, BY APPLICATIONS, 2010 – 2017 ($MILLION)
TABLE 51 EUROPE: CLOUD COMPUTING HEALTHCARE MARKET REVENUE, BY DEPLOYMENT MODELS, 2010 – 2017 ($MILLION)
TABLE 52 EUROPE: CLOUD COMPUTING HEALTHCARE MARKET REVENUE, BY COMPONENTS, 2010 – 2017 ($MILLION)
TABLE 53 EUROPE: CLOUD COMPUTING HEALTHCARE MARKET REVENUE, BY SERVICE MODELS, 2010 – 2017 ($MILLION)
TABLE 54 EUROPE: CIS CLOUD COMPUTING MARKET REVENUE, BY TYPES, 2010 – 2017 ($MILLION)
TABLE 55 EUROPE: NCIS CLOUD COMPUTING MARKET REVENUE, BY TYPES, 2010 – 2017 ($MILLION)
TABLE 56 EUROPE: CLOUD COMPUTING HEALTHCARE MARKET REVENUE, BY PRICING MODELS, 2010 – 2017 ($MILLION)
TABLE 57 ASIA: CLOUD COMPUTING HEALTHCARE MARKET REVENUE, BY APPLICATIONS, 2010 – 2017 ($MILLION)
TABLE 58 ASIA: CLOUD COMPUTING HEALTHCARE MARKET REVENUE, BY DEPLOYMENT MODELS, 2010 – 2017 ($MILLION)
TABLE 59 ASIA: CLOUD COMPUTING HEALTHCARE MARKET REVENUE, BY COMPONENTS, 2010 – 2017 ($MILLION)
TABLE 60 ASIA: CLOUD COMPUTING HEALTHCARE MARKET REVENUE, BY SERVICE MODELS, 2010 – 2017 ($MILLION)
TABLE 61 ASIA: CIS CLOUD COMPUTING MARKET REVENUE, BY TYPES, 2010 – 2017 ($MILLION)
TABLE 62 ASIA: NCIS CLOUD COMPUTING MARKET REVENUE, BY TYPES, 2010 – 2017 ($MILLION)
TABLE 63 ASIA: CLOUD COMPUTING HEALTHCARE MARKET REVENUE, BY PRICING MODELS, 2010 – 2017 ($MILLION)
TABLE 64 ROW: CLOUD COMPUTING HEALTHCARE MARKET REVENUE, BY APPLICATIONS, 2010 – 2017 ($MILLION)
TABLE 65 ROW: CLOUD COMPUTING HEALTHCARE MARKET REVENUE, BY DEPLOYMENT MODELS, 2010 – 2017 ($MILLION)
TABLE 66 ROW: CLOUD COMPUTING HEALTHCARE MARKET REVENUE, BY COMPONENTS, 2010 – 2017 ($MILLION)
TABLE 67 ROW: CLOUD COMPUTING HEALTHCARE MARKET REVENUE, BY SERVICE MODELS, 2010 – 2017 ($MILLION)
TABLE 68 ROW: CIS CLOUD COMPUTING MARKET REVENUE, BY TYPES, 2010 – 2017 ($MILLION)
TABLE 69 ROW: NCIS CLOUD COMPUTING MARKET REVENUE, BY TYPES, 2010 – 2017 ($MILLION)
TABLE 70 ROW: CLOUD COMPUTING HEALTHCARE MARKET REVENUE, BY PRICING MODELS, 2010 – 2017 ($MILLION)
TABLE 71 MERGERS & ACQUISITIONS, 2010 – 2012
TABLE 72 COLLABORATIONS/PARTNERSHIPS/AGREEMENTS/JOINT VENTURES, 2009 – 2012
TABLE 73 NEW PRODUCTS DEVELOPMENT, 2009 – 2012
TABLE 74 OTHERS, 2009 - 2012
TABLE 75 AGFA: TOTAL REVENUE AND R&D EXPENSES, 2009 - 2011 ($MILLION)
TABLE 76 AGFA: TOTAL REVENUE, BY SEGMENTS, 2009 - 2011 ($MILLION)
TABLE 77 AGFA: TOTAL REVENUE, BY GEOGRAPHY, 2009 - 2011 ($MILLION)
TABLE 78 APPLE: TOTAL REVENUE AND R&D EXPENDITURE,  2009 – 2011 ($MILLION)
TABLE 79 APPLE: TOTAL REVENUE, BY GEOGRAPHY, 2009 - 2011 ($MILLION)
TABLE 80 ATHENAHEALTH, INC.: TOTAL REVENUE AND R&D EXPENSES, 2009 - 2011 ($MILLION)
TABLE 81 ATHENAHEALTH, INC.: TOTAL REVENUE, BY SEGMENTS, 2009 - 2011 ($MILLION)
TABLE 82 CISCO: TOTAL REVENUE AND R&D EXPENSES, 2009 – 2011 ($MILLION)
TABLE 83 CISCO: TOTAL REVENUE, BY GEOGRAPHY, 2009 - 2011 ($MILLION)
TABLE 84 COMPUWARE, CORP.: TOTAL REVENUE AND R&D EXPENSES,  2009 - 2011 ($MILLION)
TABLE 85 COMPUWARE, CORP.: TOTAL REVENUE, BY PRODUCTS,  2009 - 2011 ($MILLION)
TABLE 86 COMPUWARE, CORP.: TOTAL REVENUE, BY GEOGRAPHY, 2009 - 2011 ($MILLION)
TABLE 87 DELL, INC.: TOTAL REVENUE AND R&D EXPENSES, 2009 - 2011 ($MILLION)
TABLE 88 DELL, INC.: TOTAL REVENUE, BY SEGMENTS, 2009 - 2011 ($MILLION)
TABLE 89 DELL, INC.: TOTAL REVENUE, BY GEOGRAPHY, 2009 - 2011 ($MILLION)
TABLE 90 EMC CORP.: TOTAL REVENUE AND R&D EXPENSES, 2009 - 2011 ($MILLION)
TABLE 91 EMC CORP.: TOTAL REVENUE, BY SEGMENTS, 2009 - 2011 ($MILLION)
TABLE 92 EMC CORP.: TOTAL REVENUE, BY GEOGRAPHY, 2009 - 2011 ($MILLION)
TABLE 93 HEWLETT-PACKARD CO.: TOTAL REVENUE AND R&D EXPENSES, 2009 - 2011 ($MILLION)
TABLE 94 HEWLETT-PACKARD CO.: TOTAL REVENUE, BY SEGMENTS, 2009 - 2011 ($MILLION)
TABLE 95 HEWLETT-PACKARD CO.: TOTAL REVENUE, BY GEOGRAPHY, 2009 - 2011 ($MILLION)
TABLE 96 IBM: TOTAL REVENUE AND R&D EXPENSES, 2009 – 2011 ($MILLION)
TABLE 97 IBM: TOTAL REVENUE, BY GEOGRAPHY, 2009 – 2011 ($MILLION)
TABLE 98 INTEL: TOTAL REVENUE AND R&D EXPENSES, 2009 - 2011 ($MILLION)
TABLE 99 INTEL: TOTAL REVENUE, BY SEGMENTS, 2009 - 2011 ($MILLION)
TABLE 100 INTEL: TOTAL REVENUE, BY GEOGRAPHY, 2009 - 2011 ($MILLION)
TABLE 101 IRON MOUNTAIN, INC.: TOTAL REVENUE AND R&D EXPENSES, 2009 - 2011 ($MILLION)
TABLE 102 IRON MOUNTAIN, INC.: TOTAL REVENUE, BY BUSINESS SEGMENTS, 2009 - 2011 ($MILLION)
TABLE 103 IRON MOUNTAIN, INC.: TOTAL REVENUE, BY GEOGRAPHY,  2009 - 2011 ($MILLION)
TABLE 104 MERGE HEALTHCARE, INC.: TOTAL REVENUE AND R&D EXPENSES, 2009 - 2011 ($MILLION)
TABLE 105 MERGE HEALTHCARE, INC.: TOTAL REVENUE, BY SEGMENTS, 2009 - 2011 ($MILLION)
TABLE 106 MERGE HEALTHCARE, INC.: TOTAL REVENUE, BY GEOGRAPHY, 2009 - 2011 ($MILLION)
TABLE 107 MICROSOFT CORP.: TOTAL REVENUE AND R&D EXPENSES, 2009 - 2011 ($MILLION)
TABLE 108 MICROSOFT CORP.: TOTAL REVENUE, BY SEGMENTS, 2009 - 2011 ($MILLION)
TABLE 109 MICROSOFT CORP.: TOTAL REVENUE, BY GEOGRAPHY, 2009 - 2011 ($MILLION)
TABLE 110 ORACLE CORP.: TOTAL REVENUE AND R&D EXPENSES, 2009 - 2011 ($MILLION)
TABLE 111 ORACLE CORP.: TOTAL REVENUE, BY SEGMENTS, 2009 - 2011 ($MILLION)
TABLE 112 ORACLE CORP.: TOTAL REVENUE, BY GEOGRAPHY, 2009 - 2011 ($MILLION)
TABLE 113 RACKSPACE HOSTING, INC.: TOTAL REVENUE AND R&D EXPENSES, 2009 - 2011 ($MILLION)
TABLE 114 RACKSPACE HOSTING, INC.: TOTAL REVENUE, BY SEGMENTS,  2009 - 2011 ($MILLION)
TABLE 115 RACKSPACE HOSTING, INC.: TOTAL REVENUE, BY GEOGRAPHY, 2009 - 2011 ($MILLION)
TABLE 116 VMWARE, INC.: TOTAL REVENUE AND R&D EXPENSES, 2009 - 2011 ($MILLION)
TABLE 117 VMWARE, INC.: TOTAL REVENUE, BY PRODUCT CLASS, 2009 - 2011 ($MILLION)
TABLE 118 VMWARE, INC.: TOTAL REVENUE, BY GEOGRAPHY, 2009 - 2011 ($MILLION)

LIST OF FIGURES

FIGURE 1 TRADITIONAL ECOSYSTEM VS THE CLOUD ECOSYSTEM IN HEALTHCARE
FIGURE 2 CLOUD COMPUTING HEALTHCARE MARKET SEGMENTATION
FIGURE 3 CLOUD COMPUTING HEALTHCARE MARKET: DRIVERS & RESTRAINTS
FIGURE 4 FLOW OF A PHARMACY INFORMATION SYSTEM
FIGURE 5 CLOUD COMPUTING ARCHITECTURE, BY DEPLOYMENT MODELS
FIGURE 6 GLOBAL CLOUD COMPUTING MARKET SHARE, BY SERVICE MODELS, 2010 – 2017
FIGURE 7 CLOUD COMPUTING HEALTHCARE MARKET SHARE, BY GEOGRAPHY,  2011 VS 2017 (%)
FIGURE 8 KEY GROWTH STRATEGIES, APRIL 2009 – MAY 2012

Epidemiology: Malignant Melanoma – Increasing by roughly 3% annually and affecting all age groups

During the forecast period, incident cases of malignant melanoma of the skin will continue to increase across the seven major markets. This increase will be due to a combination of increasing incidence rates and population growth and will be strongest in the US and the five major EU markets. Malignant melanoma is rare in Japan and will increase more slowly over the forecast period.

Features and benefits

• Gain insight into market potential including a robust 10-year epidemiology forecast of malignant melanoma incident cases.
• Understand the key epidemiologic risk factors associated with malignant melanoma.

Highlights

The World Health Organization has reported that the incidence of malignant melanoma is increasing faster than any other cancer in the world. Amount of and susceptibility to ultraviolet exposure are the key risk factors for malignant melanoma and are driving the increase in incidence in all age groups.

Datamonitor estimates that 125,700 people were diagnosed with malignant melanoma in the seven major markets in 2011. Age-specific incidence rates will increase uniformly between 2011 and 2021. Combined with growing populations, this will cause a 35% increase during the forecast period, bringing the number of incident cases to 170,200 in 2021.

Buy your copy of this report @ http://www.reportsnreports.com/reports/165051-epidemiology-malignant-melanoma-increasing-by-roughly-3-annually-and-affecting-all-age-groups.html

Report Details:
Published: April 2012
No. of Pages: 31
Price: Single User License: US$5700  Corporate User License: US$14250



Table Of contents

OVERVIEW
Catalyst
Summary

EXECUTIVE SUMMARY
Malignant melanoma epidemiology
Malignant melanoma forecast

DISEASE DEFINITION AND DIAGNOSTIC CRITERIA
Module scope

GLOBAL VARIATION AND HISTORICAL TRENDS
Steady increases in malignant melanoma incidence since the 1970s
Malignant melanoma incidence varies by latitude

DRIVERS OF MALIGNANT MELANOMA EPIDEMIOLOGY
Outdoor exposure to ultraviolet light is undoubtedly associated with malignant melanoma
Indoor tanning increasing in popularity and probably a risk factor for malignant melanoma
Light skin color and nevus presence associated with increased malignant melanoma incidence

EPIDEMIOLOGIC FORECASTING OF MALIGNANT MELANOMA
Overview
Subpopulations
Age
Stage
BRAF mutation
Analysis of the seven major markets
Sources used
Methods

EPIDEMIOLOGIC RESULTS
Estimated incident cases
Segmentation of incident cases by age and gender
Segmentation of incident cases by stage
Segmentation of incident cases by BRAF mutation
Age-standardized rates

DISCUSSION
Growth in melanoma incidence has been steady for 4 decades and is continuing
Strengths and limitations of Datamonitor’s epidemiologic projections

BIBLIOGRAPHY
Journal papers
Websites

APPENDIX
Module methodology

List Of Tables


Table: Cancer registry data sources for the seven major markets
Table: Incident cases of malignant melanoma in the seven major markets, 2011–21
Table: Incident cases of malignant melanoma in the seven major markets, by age, 2011
Table: Incident cases of malignant melanoma in the seven major markets, by stage, 2011
Table: Incident cases of malignant melanoma in the seven major markets, by BRAF mutation, 2011

Growth Opportunities in Sports Nutrition

This report details the opportunities, legislative pressures and product concepts driving the sport nutrition industry. Insight is offered as regards the development of the market over the next four years together with the trends that will drive the sector over this period. The content provides market data and examines key examples of industry consolidation and implications for the market.

Features and benefits

• Identify geographic opportunities from global sales data backed by category analysis for North America and key countries in EU including the UK.
• Review brand and innovation strategies of key players in the performance nutrition categories.
• Examine key threats and opportunities presented by changing regulations.
• Understand the factors driving industry consolidation and examine the key deals of the recent past.
• Review category trends and new product development from existing and emerging brands in the sports nutrition category.

Highlights
Whey protein is being incorporated into a number of products, such as oatmeal and snack bars, and it can bring various health related benefits, including minimizing the loss of muscle mass. This is of obvious interest to active, healthy people but it is also relevant to seniors who may experience losses in body mass and strength.
Industry consolidation has been a significant feature of the sports nutrition industry over the past few years. This activity has included GSK's purchase of Maxinutrition, Abbott's acquisition of EAS, Glanbia’s purchase of BSN and also the Carlyle Group's $3.8bn capture of NBTY, the maker of Nature's Bounty, MET-Rx and Solgar supplements.
In the UK alone GlaxoSmithKline, parent company of Lucozade and Maximuscle, now has approximately 80,000 chillers and vending machines. This provides an incredible distribution reach for Maximuscle and its ready to drinks and nutrition bars, which could help see them further enforce their position as premier UK sports nutrition brand.

Your key questions answered

• What are the current trends and market drivers within the sports nutrition markets?
• What are the main regulatory hurdles to overcome for EU and North American Markets?
• What new ingredients and product categories present new opportunities in the field of performance nutrition?
• What is the forecast market size and growth rates to 2016 in the major sports nutrition categories and countries?
• What merger and acquisition opportunities exist in the sports nutrition market?

Buy your copy of report @ http://www.reportsnreports.com/reports/162571-growth-opportunities-in-sports-nutrition.html  

Report Details :
Published: May 2012
Pages:97
Price: Single User License:US $ 4795 Corporate User License: US$17981

Mobile Health Devices and Applications - Global Market Briefing to 2018

GlobalData’s new report, “Mobile Health Devices and Applications Global Market Briefing to 2018” provides key data, information and analysis on the global mobile health devices and applications market. It gives the market landscape, competitive landscape and market trends information for the mobile health devices and applications market, and provides comprehensive information on the key trends affecting the market, as well as key analytical content. The report also reviews the competitive landscape and technology offerings.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Mobile Health Device Market

Published: April 2012
No. of Pages: 26
Price: Single User License: US$ 2000     Corporate User License: US$6000

  


1 Table of Contents 21.1 List of Tables 3
1.2 List of Figures 3
2 Mobile Health Devices and Applications 42.1 Introduction 4
2.2 Mobile Health, Global Market Characterization 6
2.2.1 Mobile Health Market, Global, Revenue ($bn), 2010-2018 6
2.2.2 Mobile Health Market, the US, Revenue ($bn), 2010-2018 7
2.3 Mobile Health, Global, Market Dynamics 8
2.3.1 Market Drivers 8
2.3.2 Market Restraints 15
2.4 Key Players and mHealth Products 17
2.5 Key Deals 20
3 Appendix 223.1 Definitions 22
3.1.1 Mobile Health (mHealth) 22
3.2 Acronyms 23
3.3 Sources 24
3.4 Research Methodology 24
3.5 Secondary Research 25
3.6 Primary Research 25
3.7 Models 25
3.8 Forecasts 26
3.9 Expert Panels 26
3.10 GlobalData Consulting 26
3.11 Contact Us 26
3.12 Disclaimer 26
List of Tables
Table 1: Mobile Health Market, Global, Revenue ($bn), 2010-2018* 6
Table 2: Mobile Health Market, The US, Revenue ($bn), 2010-2018* 7
Table 3: Remote Patient Monitoring Market, Global, by Segment, Revenue ($m), 2004-2018 8
Table 4: Venture Capital Investments in Mobile Health ($m), 2010-2011 14
Table 5: Mobile Health Ventures of Key Players in the Medical Imaging Information Systems (MIS) Market, 2011 17
Table 6: Number of Health Applications, by Vendor Store, 2010 18
Table 7: Top Health Apps, Apple App Store, 2011 19
Table 8: Mobile Health Market, Key Deals, 2011-2012* 20

Epidemiology: Parkinson’s Disease – Aging population drives up prevalence

In this report, Datamonitor has estimated that there were a total of 2.3 million cases of Parkinson’s disease in 2011 in the seven major markets, with nearly a third of these being in the US. Incidence rates are expected to remain constant, while total prevalence rates will increase as a result of the aging population in the seven major markets.

Features and benefits

• Gain insight into market potential, including a robust 10-year epidemiology forecast of prevalent Parkinson's disease cases.
• Understand the key epidemiologic risk factors associated with Parkinson's disease.

Your key questions answered

• What are the most robust epidemiologic studies for Parkinson's disease prevalence data?
• How will the patient population change through to 2021 in the US, Japan, and the five major EU markets (France, Germany, Italy, Spain, and the UK)?
• How do changes in population structure and risk factors affect the trend in prevalent Parkinson's disease cases?

Parkinson’s Disease Market

Published: April 2012
No. of Pages: 35
Price: Single User License: US$ 5700     Corporate User License: US$14250

 

Few points from Table of Contents
OVERVIEW
Catalyst
Summary

EXECUTIVE SUMMARY
Parkinson’s disease epidemiology
Parkinson’s disease in the seven major markets
Datamonitor’s forecast of Parkinson’s disease epidemiology

DISEASE DEFINITION AND DIAGNOSTIC CRITERIA
Disease definition

GLOBAL VARIATION AND HISTORICAL TRENDS
Population structure-influenced Parkinson's disease prevalence rates across the world
Asia: highest prevalence in rural China
Americas: wide prevalence rates range in South America
Europe: sampling methods influenced prevalence rates
Prevalence rates differences: attributed to environmental differences
Historical trend: no changes in Parkinson's disease prevalence in the last 4 decades
Prevalence: increases sharply with age
Incidence: disease burden rising due to population increases and aging
Survival: dependent on co-morbidities
Mortality: improved treatment has lowered Parkinson's disease-related mortality

DRIVERS OF PARKINSON’S DISEASE EPIDEMIOLOGY
Risk factors that affect Parkinson’s disease epidemiology
Genetics and demographics
Age: strongest risk factor
Genetic predisposition: strong in patients under 50
Gender: more prevalent in males
Lifestyle factors
Lifestyle factors: role of smoking and diet
Other factors
Agricultural chemicals: strongest environmental risk factors

Personal Accident and Health Insurance in the Philippines, Key Trends and Opportunities to 2016

Natural disasters such as Typhoon Ondoy, which caused widespread damage in the Philippines in 2009, and recent events in neighboring countries such as Japan, have significantly increased Philippine consumer awareness of the need for, and benefits of, insurance. The Philippine personal accident and health insurance segment grew at a healthy rate during the review period. This growth was fuelled by the country’s rising healthcare expenditure, the increasing disposable income of much of the Philippine population, and the growing number of private hospitals in the country. As of 2011, private hospitals account for 65% of the total hospitals available in the country.

Reasons To Buy

• Make strategic business decisions using top-level historic and forecast market data related to the Philippine personal accident and health insurance market and each sector within it
• Understand the demand-side dynamics, key market trends and growth opportunities within the Philippine personal accident and health insurance market
• Assess the competitive dynamics in the personal accident and health insurance market, along with the reinsurance segment
• Identify the growth opportunities and market dynamics within key product categories
• Gain insights into key regulations governing the Philippine personal accident and health insurance market and its impact on companies and the market's future

Philippines Personal Accident & Health Insurance

Published: March 2012
No. of Pages: 178
Price: Single User License: US$ 1950    Corporate User License: US$ 3900



The report provides top-level market analysis, information and insights into the Philippine personal accident and health insurance market, including:

• The Philippine personal accident and health insurance market’s growth prospects by personal accident and health insurance categories
• The various distribution channels in the Philippine personal accident and health insurance market
• The competitive landscape in the personal accident and health insurance market
• A description of the personal accident and health reinsurance market in the Philippines

Scope
This report provides a comprehensive analysis of the personal accident and health insurance market in the Philippines:

• It provides historical values for the Philippine personal accident and health insurance market for the report’s 2007–2011 review period and forecast figures for the 2012–2016 forecast period
• It offers a detailed analysis of the key sub-segments in the Philippine personal accident and health insurance market, along with market forecasts until 2016
• It covers an exhaustive list of parameters, including written premium, incurred loss, loss ratio, commissions and expenses, combined ratio, frauds and crimes, total assets, total investment income and retentions
• It analyses the various distribution channels for personal accident and health insurance products in the Philippines
• Using Porter’s industry-standard “Five Forces” analysis, it details the competitive landscape in the Philippines for the personal accident and health insurance business
• It provides a detailed analysis of the reinsurance market in the Philippines and its growth prospects
• It profiles the top personal accident and health insurance companies in the Philippines and outlines the key regulations affecting them

Browse all Banking and Finance Reports @ http://www.reportsnreports.com/market-research/banking-services/

Global Markets for Telemedicine Technologies

REPORT HIGHLIGHTS
The global telemedicine market is expected to grow from $9.8 billion in 2010 to $11.6 billion in 2011, and to $27.3 billion in 2016, a compound annual growth rate (CAGR) of 18.6% over the next five years.
The telehospital/clinic market segment was worth $8.1 billion in 2011. This is expected to grow to $17.6 billion in 2016, demonstrating a CAGR of 16.8% between 2011 and 2016.
The telehome segment is growing faster than the telehospital/clinic segment. This market segment was valued at $3.5 billion in 2011, and this revenue is expected to grow at a CAGR of 22.5%, reaching $9.7 billion in 2016

INTENDED AUDIENCE
This report is intended for telemedicine hardware manufacturers, software providers, telecom and networking companies, the healthcare industry and healthcare insurance companies. Key takeaways include the identification and quantification of markets for technology and services in the telemedicine market. Opportunities are defined in terms of market forecasts, avenues, trends, market drivers and competitive gaps.

TELEMEDICINE HARDWARE MANUFACTURERS
This includes hardware manufacturers of home care units (e.g., vital signals), videoconferencing equipment and store-and-forward (i.e., radiological and pathological) units. The report provides market forecasts for the five-year period from 2011 through 2016. It provides analysis of recent technology developments and includes profiles of main players, benchmarking information, key buying criteria and value-chain mapping.

TELEMEDICINE SOFTWARE PROVIDERS
Market forecasts are included for telehome and telehospitals/clinics across different geographic markets.

Telemedicine Technologies Market

Published: March 2012
No. of Pages:168
Price: Single User License: US$ 4850              Corporate User License: US$ 8500 

REASONS FOR THE STUDY
Companies require clarity regarding the main markets for telemedicine technologies and services. BCC is interested in providing a comprehensive market forecast for multiple market segments (e.g., technologies, services, applications, geographical).

There has been a global focus on the use of telemedicine as a tool to cut down healthcare costs and bring about mammoth savings. Implementation of the new U.S. healthcare law will, if anything, intensify this focus, by increasing the number of people with health insurance and seeking medical services. In the near to mid-term, telemedicine technologies offer one of the few ways of enabling healthcare personnel to meet the increased demand without unacceptable delays or other forms of de facto rationing.

BCC is interested in studying the ways in which collaborative healthcare can be better and more economically implemented through telemedicine. Recently announced best practices to cut down global healthcare costs, including outsourced medical services, home-based treatment, intervention as opposed to post treatment, integrated information technology (IT) environments, increased efficiency of healthcare resources and reducing billing gaps, all point toward the increasing use of telemedicine.

BCC aims to identify the key success factors in the telemedicine market and to gauge the ways in which this market can significantly affect larger markets such as healthcare, health insurance, home care, telecommunications (telecom), networking, disease management, e-health and healthcare IT. The report is well timed, as major Tier I stakeholders are entering the telemedicine market.

TELEMEDICINE SERVICE PROVIDERS
The report provides telemedicine integrators with a market forecast of the telemedicine service market. It highlights value-added services and unique business models of telemedicine that can help to win business success.

HEALTHCARE COMPANIES
Hospitals, home care companies, disease management companies, specialists and clinics can obtain a detailed market forecast for telecardiology, teleradiology, telepsychiatry, teledermatology, telepathology and other telemedicine applications.

HEALTH INSURANCE COMPANIES
Private and government health insurance companies will get a comprehensive and in-depth understanding of the global telemedicine market and all its main players. This report provides business cases to aid their decisions when investing in telemedicine.

Global Epilepsy Market 2010-2014

This research has been prepared based on an in-depth analysis of the market with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the first-line therapies and the second-line therapies and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key questions answered in this report:

• What will the market size be in 2014 and at what rate will it grow?
• What key trends is this market subject to?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the opportunities and threats faced by each of these key vendors?
• What are the strengths and weaknesses of each of these key vendors?

2010-2014 Epilepsy Market

Published: February 2012
No. of Pages: 29
Price : Single User License - US$1500                  Corporate User License - US$2500



Table of Contents:
01. Executive Summary
02. Introduction
03. Market Coverage
04. Market Landscape
05. Vendor Landscape
06. Buying Criteria
07. Market Growth Drivers
08. Drivers and their Impact
09. Market Challenges
10. Market Trends
11. Key Vendor Analysis
11.1 Pfizer Inc.
11.2 UCB SA
11.3 GlaxoSmithKline plc.
11.4 Novartis AG
12. Other Reports in this Series

List of Exhibits:
Exhibit 1: Global Epilepsy Market 2010-2014 (US$ billion)
Exhibit 2: Global Epilepsy Market by Geographical Segmentation 2010
Exhibit 3: Global Epilepsy Market by Vendor Segmentation 2010

Brazil Pharmaceutical Market Overview – Expanding healthcare access drives double-digit sales growth now available at ReportsandReports

Dallas, TX: ReportsandReports announce it will carry Brazil Pharmaceutical Market Overview – Expanding healthcare access drives double-digit sales growth Market Research Report in its Store.

Brazil’s retail pharmaceutical market was valued at $12.6 billion in 2009, having grown by 14.3% between 2008 and 2009. Key growth drivers include the expanding population, improved access to healthcare, and the burgeoning middle class which is increasingly opting for branded drugs. Consequently, Big Pharma is targeting Brazil to off-set slowing sales growth in more developed markets.

Scope

Overview of socioeconomic and demographic trends, healthcare system, regulation, pricing, reimbursement and intellectual property position in Brazil

Assesses the size of Brazil’s pharmaceutical market by prescribing setting, therapy area, leading brands and by leading companies

Examines Brazil’s generics and biosimilars landscape in terms of regulatory issues, level of penetration, key players and degree of brand erosion

Quantifies Brazil’s R&D and manufacturing infrastructure for the leading pharmaceutical companies, including key metrics and domestic M&A analysis

Highlights

Brazil spent 10.8% of its GDP on both retail and hospital prescribed pharmaceuticals in 2009, reflecting the government’s changing priorities, prioritizing healthcare including initiatives to expand access to medicines.

Intellectual property protection remains problematic for branded pharma, with issues associated with patent linkage, drawn out patent reviews, conflict between the two agencies involved in assessing patent applications, and the fact that there is no set period of data exclusivity.

Strong market growth in conjunction with improving regulatory standards has led to Brazil becoming a hotbed for investment from both multinational and domestic companies. Big Pharma players are gaining a stronger presence through M&A, expanding operations, and new product launches.

Reasons to Purchase

• Evaluate the evolving regulatory landscape and the impact of pricing and reimbursement controls on market access in Brazil.
• Quantify the size and growth of the prescription pharmaceutical market in Brazil, analyzing key therapy areas, brands and companies.
• Assess drivers and resistors of generic and biosimilars uptake in Brazil.

Original Source : Brazil Pharmaceutical Market

Buy Now : Market Research

Table Of Contents

ABOUT DATAMONITOR HEALTHCARE 2

About the Healthcare Strategic Analysis Team 2

Geographic specific reports: 2

Global issue reports: 2

1. Brazil – Executive Summary 3

Strategic scoping and focus 3

Key findings – healthcare drivers and resistors in Brazil 4

Key findings – healthcare drivers and resistors in Brazil 4

Brazil – Socio-demographic and economic analysis 7

Socio-demographic trends 7

Socioeconomic trends 8

Brazil – Healthcare system and drug regulatory analysis 11

Brazil healthcare expenditure 11

Brazil healthcare system overview 12

Brazil regulatory issues 13

Brazil pricing and reimbursement issues 13

Brazil – Prescription pharmaceutical sales analysis 15

Pharmaceutical market size 15

Leading therapy areas 15

Leading pharmaceutical brands 15

Leading pharmaceutical companies 15

Brazil – Drug expiry analysis 17

Brazil retail generics market 17

Brazil brand erosion post patent expiry 17

Brazil biosimilars market 17

Brazil – Pharmaceutical Industry Infrastructure analysis 19

Pharmaceutical industry infrastructure overview 19

Related reports 21

Upcoming related reports 21

2. Brazil – Socio-demographic and economic analysis 23

Key findings 23

Socio-demographic trends 23

Socioeconomic trends 23

Demographic trends in Brazil 25

Brazil’s population expected to expand rapidly, peaking in 2040 26

Declining number of births with improving infant mortality rates 28

The Brazilian population is slowly aging 29

The Brazilian population is living longer 30

Disease burden in Brazil 31

Heart disease a leading cause of death in Brazil as in more developed markets 32

Violence and social deprivation still significant despite progress 33

An unexpectedly high rate of prostate cancer deaths representative of gaps in healthcare provision 34

Political climate 35

The end of the Lula government but his legacy will live on 35

The effect of the global economic crisis has been felt less in Brazil 36

PAC gives Brazil much needed infrastructure development 36

Is the Brazilian economy in danger of overheating? 37

Debt reduction a fundamental feature of Lula’s economic policy 38

Increased prosperity has brought income disparities 41

Business environment 41

Setting up business in Brazil can be complex and difficult 41

The Brazilian tax system is complicated and confusing 42

Workforce is extensive but poorly educated 42

3. Brazil – Healthcare system and drug regulatory analysis 44

Key findings 44

Brazil healthcare expenditure 44

Brazil healthcare system overview 44

Brazil regulatory issues 45

Brazil pricing and reimbursement issues 45

Healthcare system 47

Healthcare expenditure in Brazil is rising 47

Growing cost pressures may lead to a cut in the medication budget 49

Healthcare is delivered through two systems 50

The SUS provides universal healthcare coverage in Brazil 51

SUS management has become less centralized 52

Private health insurance system – most Brazilians use the SUS, but the private health segment is expanding 53

Brazil has sought to expand healthcare coverage to reduce inequalities 54

The Family Health Program reduces burden on hospitals and specialist care 54

The Popular Pharmacy program was set up to increase the supply of medicines to the poor 55

Regulatory issues in Brazil 56

Regulatory issues in Brazil 56

Drug approval and regulatory processes – pharma companies regard Brazil’s regulatory environment as unpredictable 56

ANVISA is the national body in charge of regulating medicines in Brazil 56

Similares are being phased out – bioequivalence studies are required for generic drugs in Brazil since 2003 57

Plant inspections are causing lengthy approval times in Brazil 57

ANVISA introduces a new decree on pharmacovigilance 58

Intellectual property protection in Brazil 58

The speed of patent review is slow and backlogs exist 58

There is conflict between the two agencies involved in assessing patent applications 59

There is no set period of data exclusivity in Brazil 59

Compulsory licenses on HIV/AIDS drugs were used only as a threat until May 2007 60

Pipeline patents have awarded several HIV/AIDS drugs extra protections but could be overruled in the future 61

Drug counterfeiting is on the rise in Brazil 61

Drug importation – imported pharmaceuticals have to be registered with ANVISA 62

Pricing and reimbursement in Brazil 63

Pricing issues in Brazil 63

Pricing of new drugs is controlled by the CMED 63

Prices of marketed pharmaceuticals are controlled through price freezes and increases 64

Antiretroviral therapies are priced low in Brazil 65

Reimbursement issues in Brazil – Reimbursable pharmaceuticals are included on the National list of Essential Medicines 66

The Pharmaceutical Care in Primary Healthcare program provides access to essential drugs 67

Strategic program for pharmaceutical assistance includes medicines for neglected diseases 67

The Specialist Pharmaceutical Assistance Component provides specialist and high-cost medicines 68

Despite the SUS reimbursement programs, many patients still do not have access to medicines 68

4. Brazil – Prescription pharmaceutical sales analysis 70

Key findings 70

Pharmaceutical market size 70

Leading therapy areas 70

Leading pharmaceutical brands 70

Leading pharmaceutical companies 70

Pharmaceutical market size in Brazil 72

Leading therapy areas in Brazil 74

Central nervous system was the largest therapy area in terms of sales 76

Musculoskeletal drugs have shown the fastest growth rates 76

Urology and metabolic have shown the slowest growth rates 77

Leading pharmaceutical brands in Brazil 78

Top-selling drug Dorflex sees its franchise extended with follow-up product 81

Cialis to maintain momentum thanks to lifecycle management strategy 81

Lipitor is expected to continue reaching high sales even after patent expiration 81

Leading pharmaceutical companies in Brazil 82

Sanofi-Aventis is now the leading pharma company in Brazil following its acquisition of Medley

Novartis’s Brazilian retail sales growth driven by its Diovan franchise 84

The leading domestic companies are exhibiting double-digit growth rates 86

EMS 87

Eurofarma 87

Neo Quimica 88

5. Brazil – Drug expiry analysis 89

Key findings 89

Brazil retail generics market 89

Brazil brand erosion post patent expiry 89

Brazil biosimilars market 89

Brazilian generics market dynamics 91

Similares versus true generics 92

Brazilian generics volume uptake 94

Brazilian generics value uptake 95

Brazilian generics market size 96

Drivers and resistors in the Brazilian generics market 97

Several legislative measures have driven generic uptake 98

Loose patent regulations lead to increased market potential for generic players 99

Market pressures drive down generics prices below the mandatory 35% discount 99

International pressures could hamper generics importers 100

Similares provide affordable healthcare, but bioequivalence legislation has fueled the uptake of true generics 100

Key generics players in the Brazilian market 101

Acquiring local generics players is key strategy for foreign players to penetrate the Brazilian market 102

Sanofi-Aventis extends its dominance in Brazil 103

Pfizer seeks to extend its presence in Brazil 104

Valeant acquires two Brazilian generic drug companies 105

Lupin committed to gaining ground in Brazil 105

Opportunities for the generics industry 106

Small molecule brand erosion in the Brazilian market 107

Number of generic entrants by therapy area 107

Brazil biosimilars market dynamics 108

Drivers and resistors of biosimilar growth in Brazil 108

Rising healthcare costs 108

Biosimilars approval process enacted in 2005 109

Indian-based companies dominate the market 109

New and future biosimilar launches 111

Opportunities for the biosimilar industry 112

Monoclonal antibody therapies could soon face biosimilar incursion in Brazil 113

Biosimilars in development internationally 115

6. Brazil – Pharmaceutical Industry Infrastructure analysis 116

Key findings 116

Pharmaceutical industry infrastructure overview 116

Key company infrastructure in Brazil 117

EMS 118

Novartis 121

Ache Labs 125

Medley 128

Sanofi-Aventis 128

Eurofarma 131

Pfizer 134

Bayer Schering 138

Castro Marques 141

Merck & Co. 143

7. Bibliography 147

Brazil – Executive summary 147

Publications and online articles 147

Brazil – Socio-demographic and economic analysis 148

Publications and online articles 148

Datamonitor reports and products 151

Brazil – Healthcare systems and regulations 151

Publications and online articles 151

Datamonitor reports and products 155

Brazil – Prescription pharmaceutical sales 155

Publications and online articles 155

Brazil – Drug expiry analysis 156

Publications and online articles 156

Datamonitor reports and products 159

Brazil – Pharmaceutical industry infrastructure analysis 160

Publications and online articles 160

Datamonitor reports and products 161

APPENDIX 162

Exchange rates used in this report 162

Datamonitor prescription pharmaceutical definition and therapy area classification 163

About Datamonitor 164

About Datamonitor Healthcare 164

Datamonitor consulting 164

Disclaimer 165

Disclaimer 166

Browse complete Report on: Brazil Pharmaceutical Market Overview – Expanding healthcare access drives double-digit sales growth

Browse all Healthcare Market Research Reports

Browse all Datamonitor Market Research Reports

Browse all Newly Published Market Research Reports

Related Reports:

The Healthcare System and Delivery Network in Emerging Economies (China, India and Brazil) – Growth Opportunities Driven by Awareness, Affordability and Access

Australia Pharmaceutical Market Overview – Reforms and continued price cuts will change the healthcare landscape

Pipeline Insight: Benign Prostatic Hyperplasia – Novel therapeutics and reformulations will drive market growth

US Surgical Sutures Market: Surgical Procedures Growth to Drive Demand

US Spinal Surgery Devices Market: Increasing Procedures to Drive Growth

About Us:

Reports and Reports comprises an online library of 10,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites. Our client list boasts almost all well-known publishers of such reports across the globe. We as a third-party reseller of market research reports employ a number of marketing tools, such as press releases, email-marketing and effective search-engine optimization techniques to drive revenues for our clients. We also provide 24/7 online and offline support service to our customers.

Contact:

Ms. Sunita

7557 Rambler road,

Suite 727, Dallas, TX 75231

Tel: +1-888-989-8004

Website: http://www.reportsandreports.com/

Blog: http://reportsnreports.wordpress.com/

Blog: http://reportsandreports.blogspot.com/